Notably, the inhibition of either DNMT1 or BCL11A results in a compromised capacity for cancer stemness and tumorigenesis in TNBC, which is achieved through the suppression of ISL1 expression both in vivo and in vitro. The gene discussed is DNMT1; the disease is cancer.